The relationship between cognitive impairment in schizophrenia and metabolic syndrome: A systematic review and meta-analysis

Psychological Medicine

Volumn 47, Issue 6, 2017, Pages 1030-1040

  Bora, E ^a,b   Akdede, B B ^b   Alptekin, K ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Cognition; diabetes mellitus; dyslipidemia; hypertension; metabolic syndrome; obesity; schizophrenia

Indexed keywords

COGNITIVE DEFECT; COMORBIDITY; DIABETES MELLITUS; HUMAN; META ANALYSIS; METABOLIC SYNDROME X; SCHIZOPHRENIA;

COGNITIVE DYSFUNCTION; COMORBIDITY; DIABETES MELLITUS; HUMANS; METABOLIC SYNDROME; SCHIZOPHRENIA;

EID: 85007483034     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291716003366     Document Type: Review

References (52)

1. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S (2013). Prevalence and trends of metabolic syndrome in the adult U.S population, 1999-2010. Journal of American College of Cardiology 62, 697-703.
2. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006). Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurology 5, 64-74.
3. Bora E (2015). Neurodevelopmental origin of cognitive impairment in schizophrenia. Psychological Medicine 45, 1-9.
4. Bora E, Murray RM (2014). Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophrenia Bulletin 40, 744-755.
5. Bora E, Pantelis C (2013). Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. Schizophrenia Research 144, 31-36.
6. Bora E, Yucel M, Pantelis C (2009). Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. British Journal of Psychiatry 195, 475-482.
7. Bora E, Yücel M, Pantelis C (2010). Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophrenia Bulletin 36, 36-42.
8. Botis AC, Miclutia I, Vlasin N (2016). Cognitive function in female patients with schizophrenia and metabolic syndrome. European Psychiatry 33 (Suppl.), S99.
9. Boyer L, Richieri R, Dassa D, Boucekine M, Fernandez J, Vaillant F, Padovani R, Auquier P, Lancon C (2013). Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatry Research 210, 381-386.
10. Boyer L, Testart J, Michel P, Richieri R, Faget-Agius C, Vanoye V, Auquier P, Lancon C, Guedj E (2014). Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: a structural equation modeling approach. Psychoneuroendocrinology 50, 95-105.
11. de Nijs J, Pet MA, GROUP Investigators (2016). Metabolic syndrome in schizophrenia patients associated with poor premorbid school performance in early adolescence. Acta Psychiatrica Scandinavica 133, 289-297.
12. Depp CA, Strassnig M, Mausbach BT, Bowie CR, Wolyniec P, Thornquist MH, Luke JR, McGrath JA, Pulver AE, Patterson TL, Harvey PD (2014). Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. Bipolar Disorders 16, 422-431.
13. Farr OM, Tsoukas MA, Mantzoros CS (2015). Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders. Metabolism 64, 114-130.
14. Friedman JI, Tang CY, de Haas HJ, Changchien L, Goliasch G, Dabas P, Wang V, Fayad ZA, Fuster V, Narula J (2014). Brain imaging changes associated with risk factors for cardiovascular and cerebrovascular disease in asymptomatic patients. JACC Cardiovascular Imaging 7, 1039-1053.
15. Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL (2010). The effects of hypertension and body mass index on cognition in schizophrenia. American Journal of Psychiatry 167, 1232-1239.
16. Goughari AS, Mazhari S, Pourrahimi AM, Sadeghi MM, Nakhaee N (2015). Associations between components of metabolic syndrome and cognition in patients with schizophrenia. Journal of Psychiatric Practice 21, 190-197.
17. Green MF (2016). Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. Journal of Clinical Psychiatry 77 (Suppl.), 8-11.
18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr. SC, Spertus JA, Fernando Costa (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112, 2735-2752.
19. Guo X, Zhang Z, Wei Q, Lv H, Wu R, Zhao J (2013). The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry 13, 109.
20. Guo X, Zhang Z, Zhu W, Lian N, Lu H, Zhao J (2011). Cognitive functioning in schizophrenia with or without diabetes. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36, 724-727.
21. Hadhoud KM, Fouad AA (2013). Effect of diabetes and schizophrenia on cognitive function in Egyptians. Zagazig University Medical Journal 19, 619-627.
22. Han M, Huang XF, Chen da C, Xiu M, Kosten TR, Zhang XY (2013). Diabetes and cognitive deficits in chronic schizophrenia: a case-control study. PLoS ONE 8, e66299.
23. Handley JD, Williams DM, Caplin S, Stephens JW, Barry J (2016). Changes in cognitive function following bariatric surgery: a systematic review. Obesity Surgery 26, 2530-2537.
24. Lancon C, Dassa D, Fernandez J, Richieri R, Padovani R, Boyer L (2012). Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study. Cardiovascular Psychiatry Neurology 2012, 204043.
25. Laursen TM, Munk-Olsen T, Vestergaard M (2012). Life expectancy and cardiovascular mortality in persons with schizophrenia. Current Opinion in Psychiatry 25, 83-88.
26. Leung A, Chue P (2000). Sex differences in schizophrenia, a review of the literature. Acta Psychiatrica Scandinavica Suppl 401, 3-38.
27. Li C, Zhan G, Rao S, Zhang H (2014). Metabolic syndrome and its factors affect cognitive function in chronic schizophrenia complicated by metabolic syndrome. Journal of Nervous and Mental Disease 202, 313-318.
28. Lindenmayer JP, Khan A, Kaushik S, Thanju A, Praveen R, Hoffman L, Cherath L, Valdez G, Wance D (2012). Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophrenia Research 142, 171-176.
29. McEvoy JP (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates fromNHANES III. Schizophrenia Research 80, 19-32.
30. McGlashan TH, Fenton WS (1993). Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophrenia Bulletin 19, 71-84.
31. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ (2009). Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23, 315-336.
32. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RSE, Stroup TS, Lieberman JA (2005). The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 80, 9-18.
33. Micoulaud-Franchi JA, Faugere M, Boyer L, Cermolacce M, Richieri R, Faget C, Philip P, Vion-Dury J, Lancon C (2015). Association of metabolic syndrome with sensory gating deficits in patients with chronic schizophrenia. Psychoneuroendocrinology 57, 125-133.
34. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M (2013b). Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophrenia Bulletin 239, 295-305.
35. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013a). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophrenia Bulletin 39, 306-318.
36. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. British Medical Journal 339, b2535.
37. Morgan VA, McGrath JJ, Jablensky A, Badcock JC, Waterreus A, Bush R, Carr V, Castle D, CohenM, Galletly C, Harvey C, Hocking B, McGorry P, Neil AL, Saw S, Shah S, Stain HJ, Mackinnon A (2014). Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychological Medicine 44, 2163-2176.
38. Nasrallah H (2015). Elevated cholesterol and triglycerides are associated with better cognitive functioning in schizophrenia data from the CATIE study. Poster presented at the 168th Meeting of the American Psychiatric Association, Toronto.
39. NCEP (2001). Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 285, 2486-2497.
40. Qiu C, Fratiglioni L (2015). A major role for cardiovascular burden in age-related cognitive decline. Nature Reviews Cardiology 12, 267-277.
41. Rashid NA, Lim J, LamM, Chong SA, Keefe RS, Lee J (2013). Unraveling the relationship between obesity, schizophrenia and cognition. Schizophrenia Research 151, 107-112.
42. Savla GN, Vella L, Armstrong CC, Penn DL, Twamley EW (2013). Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophrenia Bulletin 39, 979-992.
43. Siervo M, Arnold R, Wells JC, Tagliabue A, Colantuoni A, Albanese E, Brayne C, Stephan BC (2011). Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta-analysis. Obesity Review 12, 968-983.
44. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ (2015). The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatrica Scandinavica 132, 144-157.
45. Szöke A, Trandafir A, Dupont ME, Méary A, Schürhoff F, Leboyer M (2008). Longitudinal studies of cognition in schizophrenia: meta-analysis. British Journal of Psychiatry 192, 248-257.
46. Takayanagi Y, Cascella NG, Sawa A, Eaton WW (2012). Diabetes is associated with lower global cognitive function in schizophrenia. Schizophrenia Research 142, 183-187.
47. van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ (2009). Type 2 diabetes mellitus, hypertension, dyslipidemia, and obesity: a systematic comparison of their impact on cognition. Biochimica et Biophysica Acta 1792, 470-481.
48. Viechtbauer W (2010). Conducting meta-analyses in R with the metafor package. Journal of Statistical Software 36, 1-48.
49. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH (2012). Closing the gap between methodologists and end-users: r as a computational back-end. Journal of Statistical Software 49, 1-15.
50. Wysoki?ski A, Dzienniak M, K?oszewska I (2013). Effect of metabolic abnormalities on cognitive performance and clinical symptoms in schizophrenia . Archives of Psychiatry and Psychotherapy 4, 13-25.
51. Yaffe K (2007). Metabolic syndrome and cognitive decline. Current Alzheimer Research 4, 123-126.
52. Zhang BH, Han M, Zhang XY, Hui L, Jiang SR, Yang FD, Tan YL, Wang ZR, Li J, Huang XF (2015). Gender differences in cognitive deficits in schizophrenia with and without diabetes. Comprehensive Psychiatry 63, 1-9.